Papillon Pharmaceutical Solutions: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Papillon Pharmaceutical Solutions
Largest movements
- Receivables after one year +€288,975
up €288,975 (+56.5%), from €511,500 to €800,475
- Cash -€278,420
down €278,420 (-45.6%), from €610,153 to €331,733
mainly Receivables after one year (-€288,975) and Current investments (-€232,802)
- Current investments +€232,802
new in 2024: €232,802
- Deferred charges and accrued income +€35,657
up €35,657 (+85.2%), from €41,852 to €77,510
- Receivables within one year +€21,331
up €21,331 (+18.3%), from €116,427 to €137,758
of which Other amounts receivable: +€28,831
- Reserves +€203,271
up €203,271 (+15.5%), from €1.3m to €1.5m
of which Distributable reserves: +€203,271
- Tax, wage and social debts +€82,019
up €82,019 (+342%), from €23,986 to €106,005
- Gross operating margin -€94,116
down €94,116 (-24.2%), from €388,833 to €294,717
- Financial income +€22,098
up €22,098 (+166%), from €13,325 to €35,423
- Taxes -€16,534
down €16,534 (-14.0%), from €117,703 to €101,169
From the 2023 result to the 2024 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2023 and 2024 balance sheets and the 2024 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2023 | 2024 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,384,801 | €1,665,455 | +€280,654 | +20.3% |
| Fixed assets | 21/28 | €104,870 | €85,178 | -€19,692 | -18.8% |
| Tangible fixed assets | 22/27 | €104,870 | €85,178 | -€19,692 | -18.8% |
| Land and buildings | 22 | €4,353 | €3,907 | -€446 | -10.3% |
| Plant, machinery and equipment | 23 | €5,530 | €5,567 | +€38 | +0.7% |
| Furniture and vehicles | 24 | €94,987 | €75,704 | -€19,283 | -20.3% |
| Current assets | 29/58 | €1,279,932 | €1,580,277 | +€300,345 | +23.5% |
| Amounts receivable after more than one year | 29 | €511,500 | €800,475 | +€288,975 | +56.5% |
| Other amounts receivable | 291 | €511,500 | €800,475 | +€288,975 | +56.5% |
| Amounts receivable within one year | 40/41 | €116,427 | €137,758 | +€21,331 | +18.3% |
| Trade receivables | 40 | €43,068 | €35,568 | -€7,500 | -17.4% |
| Other amounts receivable | 41 | €73,359 | €102,190 | +€28,831 | +39.3% |
| Current investments | 50/53 | - | €232,802 | +€232,802 | |
| Cash at bank and in hand | 54/58 | €610,153 | €331,733 | -€278,420 | -45.6% |
| Deferred charges and accrued income | 490/1 | €41,852 | €77,510 | +€35,657 | +85.2% |
| Total equity and liabilities | 10/49 | €1,384,801 | €1,665,455 | +€280,654 | +20.3% |
| Equity | 10/15 | €1,325,985 | €1,529,256 | +€203,271 | +15.3% |
| Contributions | 10/11 | €12,400 | €12,400 | = | 0.0% |
| Reserves | 13 | €1,313,585 | €1,516,856 | +€203,271 | +15.5% |
| Non-distributable reserves | 130/1 | €1,855 | €1,855 | = | 0.0% |
| Reserves not available under the articles | 1311 | €1,855 | €1,855 | = | 0.0% |
| Distributable reserves | 133 | €1,311,730 | €1,515,001 | +€203,271 | +15.5% |
| Amounts payable | 17/49 | €58,816 | €136,198 | +€77,382 | +132% |
| Amounts payable within one year | 42/48 | €58,816 | €136,198 | +€77,382 | +132% |
| Trade debts | 44 | €34,830 | €30,193 | -€4,637 | -13.3% |
| Suppliers | 440/4 | €34,830 | €30,193 | -€4,637 | -13.3% |
| Taxes, remuneration and social security | 45 | €23,986 | €106,005 | +€82,019 | +342% |
| Taxes | 450/3 | €23,986 | €106,005 | +€82,019 | +342% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €23,404 | €22,395 | -€1,009 | -4.3% |
| Other operating charges | 640/8 | €1,428 | €2,428 | +€1,000 | +70.1% |
| Gross operating margin | 9900 | €388,833 | €294,717 | -€94,116 | -24.2% |
| Operating profit (loss) | 9901 | €364,002 | €269,895 | -€94,107 | -25.9% |
| Financial income | 75/76B | €13,325 | €35,423 | +€22,098 | +166% |
| Recurring financial income | 75 | €13,325 | €35,423 | +€22,098 | +166% |
| Financial charges | 65/66B | €654 | €878 | +€224 | +34.3% |
| Recurring financial charges | 65 | €654 | €878 | +€224 | +34.3% |
| Profit (loss) for the period before taxes | 9903 | €376,673 | €304,440 | -€72,233 | -19.2% |
| Income taxes | 67/77 | €117,703 | €101,169 | -€16,534 | -14.0% |
| Profit (loss) for the period | 9904 | €258,970 | €203,271 | -€55,699 | -21.5% |
| Profit (loss) for the period to be appropriated | 9905 | €258,970 | €203,271 | -€55,699 | -21.5% |
Source: filed annual accounts (NBB), financial years ended 31 December 2023 and 31 December 2024. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 30 October 2026 via checked.be.